Evidence map›Paper›PMID 35027956›Full record

ArticleAsian journal of pharmaceutical sciences2021

Naringenin nanocrystals for improving anti-rheumatoid arthritis activity.

Guangshuai Zhang, Guangyuan Sun, Haishan Guan, Mo Li, Yanhua Liu, Baocheng Tian, Zhonggui He, Qiang Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guangshuai ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Guangyuan SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Haishan GuanWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Mo LiLiaoning Institute for Drug Control, Shenyang 110016, China.
Yanhua LiuSchool of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Baocheng TianSchool of Pharmacy, Binzhou Medical University, Yantai 264003, China.
Zhonggui HeWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Qiang FuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Naringenin (NAR) is recognized for its anti-inflammatory activity. However, the clinical application of NAR is limited by low bioavailability, which is attributed to its poor aqueous solubility. In this study, we aimed to improve the therapeutic efficacy of NAR by formulating it into nanocrystals (NCs) via wet milling. The obtained NARNCs exhibited superior dissolution behaviors, increased cellular uptake, and enhanced transcellular diffusion relative to those of bulk NAR. Oral administration of NARNCs also significantly improved bioavailability in rats. In addition, the NARNCs effectively improved rheumatoid arthritis treatment in collagen-induced arthritic rats by reducing inflammatory cell infiltration and synovial damage. These results indicate that NARNCs provides a promising strategy for rheumatoid arthritis treatment.

Indexed as

Anti-inflammationNanocrystalsNaringeninRheumatoid arthritis efficacy

Identifiers

PMID35027956
PMCPMC8740402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.